Aptose Biosciences Inc  

(Public, TSE:APS)   Watch this stock  
Find more results for tse: lor
-0.06 (-0.98%)
Jan 27 - Close
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 6.00 - 6.14
52 week 4.80 - 10.56
Open 6.14
Vol / Avg. 7,760.00/9,030.00
Mkt cap 70.67M
P/E     -
Div/yield     -
EPS -2.10
Shares 11.70M
Beta 1.03
Inst. own     -
Jan 13, 2015
Aptose Biosciences Inc at EBD Biotech Showcase

Key stats and ratios

Q3 (Sep '14) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -38.73% -66.09%
Return on average equity -41.50% -76.31%
Employees 17 -
CDP Score - -


2 Meridian Rd
+1-416-7981200 (Phone)
+1-416-7982200 (Fax)

Website links


Aptose Biosciences Inc, formerly Lorus Therapeutics Inc., is a life sciences company. The Company is focused on the discovery, research and development of effective anticancer therapies with a safety profile. The Company has worked to establish a diverse anticancer product pipeline, with products in various stages of development ranging from pre-clinical to a completed Phase I clinical trial. Intellectual property portfolio supports its diverse product pipeline.

Officers and directors

William G. Rice Ph.D. Chairman of the Board, President, Chief Executive Officer
Gregory K. Chow Chief Financial Officer, Senior Vice President
Elizabeth Williams Finance Director, IR Contact Officer
Avanish Vellanki Senior Vice President, Chief Business Officer
Stephen B. Howell M.D. Chief Medical Officer
Age: 69
Erich M. Platzer M.D., Ph.D. Director
Denis R. Burger Ph.D. Independent Director
Age: 69
Bradley Thompson Independent Director
Mark D. Vincent M.D. Independent Director
Warren Whitehead Independent Director